Chlamydia trachomatis and Mycoplasma genitalium Plasma Antibodies in Relation to Epithelial Ovarian Tumors

Table 1

Clinical characteristics for the women (291) with benign conditions, borderline ovarian tumors, epithelial ovarian cancer, or other pelvic malignancies included in the plasma antibody analyses.

Clinical characteristics	Benign conditions (𝑛=209)	BOT (𝑛=16)	EOC (𝑛=54)	Other pelvic malignancies (𝑛=12)	BOT versus benign, P value	EOC versus benign, P value
Age, y	52 (18–87)	53 (40–82)	61 (31–78)	58 (40–73)	1.0^b	.003^b
Menarche^a, y	13 (10–16), 𝑛=69	13 (11–14), 𝑛=4	13 (11–17), 𝑛=51	13 (11–16), 𝑛=8	.9^b	.06^b
Menopause^a, y	50 (40–57), 𝑛=93	50 (44–54), 𝑛=7	50 (43–61), 𝑛=41	50 (41–55), 𝑛=7	1.0^b	.2^b
Parity^a	2 (0–8), 𝑛=186	2 (0–4), 𝑛=14	2 (0–5), 𝑛=54	3 (0–3), 𝑛=11	.6^b	.8^b
0 children^a	37 (20%), 𝑛=186	1 (7%), 𝑛=14	12 (22%)	1 (9%), 𝑛=11	.5^c	.7^d
≥3 children^a	49 (26%), 𝑛=186	3 (21%), 𝑛=14	14 (26%)	6 (54%), 𝑛=11	1.0^c	.9^d
Oral contraceptive pill use ≥1 year^a	61 (73%), 𝑛=84	4 (80%), 𝑛=5	17 (37%), 𝑛=46	1 (12%), 𝑛=8	1.0^c	<.001^d
Past or current HRT use^a	37 (24%), 𝑛=152	3 (27%), 𝑛=11	14 (27%), 𝑛=52	2 (18%), 𝑛=11	.7^c	.2^d
Past or current smoking^a	54 (30%), 𝑛=183	6 (50%), 𝑛=12	18 (33%), 𝑛=54	4 (36%), 𝑛=11	.2^c	.6^d
History of PID^a	12 (34%), 𝑛=35	1 (14%), 𝑛=7	4 (9%), 𝑛=43	0 (0%), 𝑛=9	.4^c	.007^d
BMI^a	26 (19–41), 𝑛=41	24 (21–28), 𝑛=5	25 (17–34), 𝑛=53	26 (19–30), 𝑛=11	.4^b	.5^b
Prospective plasma sample >1 year prior to diagnosis	22 (11%)	0	11 (20%)	1 (8%)
Histology
Serous	𝑛=52	𝑛=9	𝑛=32	SSPC, 𝑛=7
Mucinous	𝑛=35	𝑛=7	𝑛=5
Endometrioid	𝑛=26	𝑛=0	𝑛=10	Tubal cancer, 𝑛=1; Uterine cancer, 𝑛=1; Abdominal cancer, 𝑛=1
	Follicle cyst, 𝑛=39 Brenner tumor, 𝑛=1 Theca cell tumor, 𝑛=1 Fibroma, 𝑛=6; Corpus luteum cyst, 𝑛=2; Extra uterine pregnancy, 𝑛=3; Tubo-ovarian abcess/sacto salpinx, 𝑛=6 Endometriosis, 𝑛=6 Gastrointestinal inflammation, 𝑛=3; Other, 𝑛=14; Normal, 𝑛=15		Mixed EOC, 𝑛=1; Undifferentiated EOC, 𝑛=4; Clear cell tumor, 𝑛=2	Undifferentiated tubal cancer, 𝑛=1; Undifferentiated abdominal cancer, 𝑛=1
Type 1 pathogenetic pathway			19 (35%)	3 (25%)
Type 2 pathogenetic pathway			35 (65%)	9 (75%)

Values are presented as medians and range (minimum and maximum values of age, menarche, menopause, parity, and BMI); or number and percentage of patients in each group (0 children, ≥3 children, oral contraceptive pill use ≥1 year, past or current HRT use, past or current smoking, history of PID: prospective plasma samples>1 year prior to diagnosis, type I pathogenetic pathway, and type II pathogenetic pathway).
BOT: borderline ovarian tumor; EOC: epithelial ovarian cancer; HRT: hormone replacement therapy; PID: pelvic inflammatory disease; BMI: body mass index; SSPC: Serous Surface Papillary Carcinoma.
^aVariable with partial missing data.
^bMann-Whitney U test.
^cFisher’s exact test.
^dChi-Square test.